Pharming Group Reports Financial Results for the First Quarter of 2020

Highlights:
- Delivered revenues of EUR49.3 million, an increase of 40% on Q1 2019
- Operating profit of EUR19.4 million, an increase of 59% on Q1 2019
- Despite significant one- off financial expenses of EUR3.7 million from full pay-off of loan, net profits increased by 25% to EUR8.4 million, compared to Q1 2019,

LEIDEN, Netherlands, May 14, 2020 /PRNewswire/ -- Pharming Group N.V. ("Pharming" or "the Company") presents its (unaudited) financial report for the first quarter of the year ended 31 March 2020.

Financial highlights
-- Revenues increased 40% to EUR49.3 million, compared with EUR35.2 million during the same period last year.
-- US net product sales increased to EUR47.5 million (Q1 2019: EUR33.7 million), an increase of 41% compared to the same period last year and an increase of 8.7% compared to the last quarter of 2019. This is due to the continued growth in new patients using RUCONEST® (recombinant human C1 inhibitor), balanced by the customary effect of calendar year patient insurance renewals in the US.
-- In Europe and the rest of the world, product sales increased to EUR1.8 million (Q1 2019: EUR1.3 million), an increase of 38% compared to the same period last year, following the reacquisition of RUCONEST®-licensed territories per 01 January 2020.
-- Operating profits rose by 59% to EUR19.4 million, compared to EUR12.2 million in the same period last year, mainly driven by the increased revenue.
-- Net profit increased by 25% to EUR8.4 million, compared to EUR6.7 million for Q1 2019, despite significant financial expenses of EUR7.0 million, mainly driven by EUR3.7 million one-off costs, associated with the pay-off of the Orbimed loan in early January, an increase of the contingent consideration of EUR1.2 million for the final $25 million milestone to Bausch Health and foreign currency losses of EUR1.1 million. The interest payments on the EUR125 million 2020-2025 convertible bonds only amounted to EUR0.8 million of these financial expenses, compared to the EUR3.3 million interest for the Orbimed loan that was paid during Q1 2019, reflecting the significant decrease in financing costs going forward.
-- Positive cashflows during the quarter were driven by strong revenue despite intensified competition, generating more than EUR19 million of cash above the cash required for operating costs. This was then reduced, mainly, by payment of EUR5.5 million of the total EUR7.5 million payable to Sobi for reacquisition of the EU commercialization rights to RUCONEST® and the $20 million payment (EUR18.1 million) for the penultimate sales performance milestone paid to Bausch Health Companies Inc. These payments and the balance of the repayment in full of the remaining Orbimed loan facility and the associated penalties for early repayment (totalling to EUR49.7 million) and the net proceeds of the EUR125 million convertible bonds minus interest payment, resulted in an increase in the cash position of EUR67.5 million to EUR136.1 million at 31 March 2020 (EUR68.6 million at 31 December 2019).
-- The equity position improved from EUR104.7 million at the end of December 2019 to EUR115.6 million at the end of the first quarter of 2020 (Q1 2019: EUR69.1 million). The majority of the increase in equity is related to the net result for the quarter.
-- Other financial liabilities, as stated under current liabilities, refers to the contingent consideration for the milestones and its decrease versus 31 December 2019 reflects the payment of the penultimate $20 million successful sales performance milestone in February 2020 to Bausch Health. The milestone payment of $20 million (EUR18.1 million) does not appear in the income statement because the cost of the milestone is balanced by the release of the contingent consideration liability of EUR17.8 million shown in current liabilities at the 2019 year-end, after allowing for exchange rate differences.
-- Inventories stabilized at EUR14.5 million at the end of the first quarter of 2020 compared to the end of December 2019, as a result of increasing production.
-- Since the last reporting date of 26 March 2020, the Company has issued no shares in connection with exercises of options under the current schemes. The number of issued shares as at 13 May 2020 is 634,994,764. The fully diluted number of shares as at 13 May 2020 is 741,679,325.

Operational highlights

On 14 January 2020, the Company announced the launch and placement of an over-subscribed offering (the "Offering") of EUR125 million, 3% senior unsecured convertible bonds due 2025 (the "Bonds"). The conversion price was set at EUR2.0028 which represented a premium of 40% to the volume weighted average share price (VWAP) when the placement was completed. Net proceeds of the issue of the Bonds were used to redeem the remaining $56 million of the originally $100 million loan from Orbimed Advisors in full, thereby reducing the Company's financing costs and extending its debt maturity through the period to approval of most of the Company's existing pipeline. The balance of the net proceeds will be used to support capital expenditure in relation to the expansion of the commercialisation and manufacturing infrastructure of the Company and serve as funding for the launch of Pharming's recently acquired leniolisib product and for additional acquisitions/in- licensing opportunities.

During the first quarter of 2020, Pharming received European and US validation of its new production facility of starting material for the Company's lead product, RUCONEST®. In January 2020, the European Medicines Agency (EMA) approved a Type II Variation for the new production facility. In March 2020, the US Food and Drug Administration (FDA) approved Pharming's Prior Approval Supplement to add the new production facility to the Biologics License Application (BLA) to support RUCONEST®. With the addition of this new facility, Pharming will significantly increase the production capacity of RUCONEST® as it becomes fully operational during this year.

On 11 March 2020, the Company announced its Chief Financial Officer (CFO), Robin Wright, had decided not to put himself up for re-election as a member of the Board of Management and therefore as CFO at the General Meeting of Shareholders on 20 May 2020. As a result of this decision, Robin's term with the Company will end as at that date. The search for a new Chief Financial Officer is meanwhile well underway.

On 23 March 2020, the Company announced it has been included in the Euronext Amsterdam Midkap index (AMX). Composition of the AMX is reviewed quarterly by Euronext Amsterdam. Entry eligibility into any of the Amsterdam indexes is evaluated by certain criteria, including free float/market capitalisation and free float/velocity. Based on these evaluations, Euronext ranks the companies by size into one of the three indexes; AEX, AMX or AScX of the Amsterdam stock exchange. The promotion to AMX further validates Pharming's strong growth and the success of the Company's commercialisation platform, as well as providing access to a new pool of funds mandated to invest in companies in this index.

Post period operational highlights
On 21 April 2020, the Company announced encouraging results from five patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia that were treated with RUCONEST® under a compassionate use program at the University Hospital Basel, Switzerland. Following these initial results, a multinational, randomized, controlled, investigator-initiated clinical trial with up to 150 patients with confirmed COVID-19 infections, requiring hospitalisation due to significant COVID-19 related symptoms is planned. The study will be led by Dr Michael Osthoff, University Hospital Basel, Switzerland.

On 30 April 2020, the Company announced that the European Commission approved an extension in the indication of RUCONEST®'s Marketing Authorisation to include the treatment of acute angioedema attacks in children with hereditary angioedema (HAE). The European Commission's decision allows children aged two years and older to be treated with RUCONEST® for acute angioedema attacks. In the European Union, RUCONEST® has been approved for this indication in adults since 2010 and in adolescents since 2016.

COVID-19 update

During the COVID-19 pandemic, Pharming is complying with international guidance and requirements across its operations to prioritise the health and safety of its employees.

The current impact of COVID-19 on the business is summarised below.


-- No impact on (up-scaling of) production of RUCONEST®. The Company's new
facility (approved during Q1 2020) significantly increases the
production of Pharming's therapy for HAE patients globally. In addition,
with the C1-inhibitor in RUCONEST® being plasma free, production of the
product does not rely on plasma collection centres.
-- No impact on the availability or distribution of RUCONEST® to HAE
patients; who typically self-treat their attacks at home in the US and
in certain EU countries.
-- Recruitment of new patients in ongoing clinical trials has been halted;
patients already incorporated in clinical trials will continue to
receive treatment.
-- As a result of halting recruitment; timelines for the pre-eclampsia and
acute kidney injury studies are expected to incur delays, subject to the
return of recruitment of new patients.
-- No delay is currently expected to the planned launch of leniolisib in H2
2022, as the completion date of the ongoing registration enabling study
is currently not critical for the planned launch date.
-- An Investigator-sponsored multi-centre randomised controlled clinical
trial in patients with confirmed COVID-19 infections is being prepared
and expected to start in the near future and the Company will provide an
update when the first patient is treated.
Sijmen de Vries, Chief Executive Officer of Pharming, commented:

"The start of 2020 has been very busy for Pharming. Importantly, we completed a highly successful convertible bond refinancing, replacing our existing debt facility, providing additional cash resources and further strengthening our balance sheet to support our long-term growth prospects. We also received EMA and FDA approval of our new production facility for RUCONEST®, which will double our production capacity once fully operational later this year. In addition, approval from the European Commission to treat acute HAE attacks in children with RUCONEST® allows us to serve the most vulnerable patients and further demonstrates the safety and efficacy of our lead product.

"In addition to these achievements, Pharming has continued to deliver strong sales growth as new patients continue to benefit from RUCONEST®'s product profile. Following the reacquisition of RUCONEST®-licensed territories from January 2020, we are excited to expand our distribution network in Europe, where we are seeing increasing demand for the product.

"Looking forward to the remainder of 2020, we expect continued sales growth versus last year, driven by increasing patient numbers and despite competitive pressure, whilst remaining cognisant of the macro-environment and uncertainty around COVID-19."

Financial summary

3 months to 31 March


2020 2019


%


Amounts in EURm except per
share data 1st Quarter 1st Quarter Change

---

Income Statement



Revenues 49,3 35,2 40%



Gross profit 43,9 29,8 47%



Operating result 19,4 12,2 59%



Net result 8,4 6,7 25%


Balance Sheet


Cash & marketable
securities 136,1 68,6 98%


Share Information


Earnings per share (EUR):
-Undiluted 0,013 0,011 18%


-Fully diluted 0,011 0,010 10%

Outlook

For the remainder of 2020, the Company expects:


-- Continued growth in revenues from sales of RUCONEST®, mainly driven by
the US and expanded European operations.
-- Maintenance of positive net earnings during the year.
-- Continued investment in the expansion of production of RUCONEST® in
order to ensure continuity of supply to the growing markets in the US,
Europe, China and the Rest of the World.
-- Investment in the ongoing clinical trials for pre-eclampsia and acute
kidney injury, and support for investigators wishing to explore
additional indications for RUCONEST®, such as the planned study in
patients confirmed with COVID-19 infections with related severe
pneumonia.
-- Investment in the continuing registration-enabling study for leniolisib
for APDS, leading to headline data early in 2021.
-- Investment in IND enabling studies for -glucosidase in Pompe disease
and preclinical development of the new recombinant -galactosidase
candidate for Fabry's disease.
-- Investment in other new development opportunities and assets as these
occur.
-- Increasing marketing activity where this can be profit-enhancing for
Pharming.
-- Supporting all our teams and marketing partners in order to enable the
maximisation of the potential of RUCONEST® for patients, as we continue
to believe that RUCONEST® represents an effective and reliable safe
therapy to treat acute angioedema attacks in patients with HAE.
-- Continued close monitoring of the ongoing COVID-19 pandemic and the
potential impact on the business.
No further financial guidance for 2020 is provided.

About Pharming Group N.V.

Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming's lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema ("HAE") attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorisation.

RUCONEST® is commercialised by Pharming in the US and in Europe, and the Company holds all other commercialisation rights in other countries not specified below. In some of these other countries distribution is made in association with the HAEi Global Access Program (GAP). RUCONEST® is distributed in Argentina, Colombia, Costa Rica, the Dominican Republic, Panama, and Venezuela by Cytobioteck, in South Korea by HyupJin Corporation and in Israel by Kamada.

RUCONEST® is also being evaluated for various additional indications. Pharming's technology platform includes a unique production process that has proven capable of producing industrial quantities of pure high quality recombinant human proteins in a more economical and less immunogenic way compared with current cell-line based methods.

Leads for enzyme replacement therapy ("ERT") for Pompe and Fabry's diseases are also being produced and optimised respectively at present.

Pharming has recently in-licensed leniolisib from Novartis, a small molecule and selective PI3K inhibitor, which is in a registrational study for activated PI3K-delta syndrome (APDS), a rare form of Primary Immunodeficiency.

Pharming has a long term partnership with the China State Institute of Pharmaceutical Industry ("CSIPI"), a Sinopharm company, for joint global development of new products, starting with recombinant human Factor VIII for the treatment of Haemophilia A. Preclinical development and manufacturing will take place to global standards at CSIPI and its affiliates and are funded by CSIPI. Clinical development will be shared between the partners with each partner taking the costs for their territories under the partnership.

Additional information is available on the Pharming website: www.pharming.com [http://www.pharming.com/].

Forward-looking Statements

This press release of Pharming Group N.V. and its subsidiaries ("Pharming", the "Company" or the "Group") may contain forward-looking statements including without limitation those regarding Pharming's financial projections, market expectations, developments, partnerships, plans, strategies and capital expenditures.

The Company cautions that such forward-looking statements may involve certain risks and uncertainties, and actual results may differ. Risks and uncertainties include without limitation the effect of competitive, political and economic factors, legal claims, the Company's ability to protect intellectual property, fluctuations in exchange and interest rates, changes in taxation laws or rates, changes in legislation or accountancy practices and the Company's ability to identify, develop and successfully commercialize new products, markets or technologies.

As a result, the Company's actual performance, position and financial results and statements may differ materially from the plans, goals and expectations set forth in such forward-looking statements. The Company assumes no obligation to update any forward-looking statements or information, which should be taken as of their respective dates of issue, unless required by laws or regulations.

Pharming Group N.V.

Consolidated Interim Financial Statements (Unaudited)

For the first three months ended 31 March 2020

Consolidated statement of income

Consolidated statement of comprehensive income

Consolidated balance sheet

Consolidated statement of cash flows

Appendix: Main Financial Statements reported in US dollars

(The appendix does not form part of the Consolidated Interim Financial Statements)

Consolidated statement of income in US Dollars (unaudited)

Consolidated balance sheet in US Dollars (unaudited)

Consolidated statement of cash flows in US Dollars (unaudited)

Consolidated Statement of Income

For the first three months ended 31 March


Amounts in EUR '000 except per
share data YTD 2020 YTD 2019




Revenues 49,294 35,224

---

Costs of sales (5,390) (5,420)

---

Gross profit 43,904 29,804

---

Other income 241 281

---

Research and development (8,017) (5,305)


General and administrative (5,167) (2,968)



Marketing and sales (11,515) (9,568)




Costs (24,699) (17,841)

---

Operating result 19,446 12,244

---

Fair value gain (loss) on
revaluation derivatives 121 (28)



Other financial income 370 176


Other financial expenses (7,525) (2,673)


Financial income and expenses (7,034) (2,525)

---

Share of net profits in associates
using the equity method 14

---

Result before income tax 12,426 9,719

---

Income tax credit (expense) (3,999) (2,980)


Net result for the year 8,427 6,739

---

Attributable to:



Owners of the parent 8,427 6,739


Total net result 8,427 6,739

---

Basic earnings per share (EUR) 0.013 0.011


Fully-diluted earnings per share
(EUR) 0.011 0.010

---

Consolidated Statement of Comprehensive Income

For the first three months ended 31 March



Amounts in EUR '000 YTD 2020 YTD 2019

---

Net result for the period 8,427 6,739


Currency translation differences (53) (304)


Items that may be subsequently
reclassified to profit or loss (53) (304)


Other comprehensive income
(loss), net of tax (53) (304)


Total comprehensive income (loss)
for the period 8,374 6,435


Attributable to:



Owners of the parent 8,374 6,435

---

Consolidated Balance Sheet

As at date shown



Amounts in EUR '000 March 31 December 31
2019
2020

---




Intangible assets 77,620 70,809



Property, plant and equipment 8,689 8,553



Right-of-use assets 5,581 5,979



Deferred tax assets 25,314 28,590



Investment accounted for using the equity method 5,515 5,508



Restricted cash 2,306 2,268




Non-current assets 125,025 121,707





Inventories 14,511 14,467



Trade and other receivables 30,564 25,737



Cash and cash equivalents 133,834 66,299




Current assets 178,909 106,503






Total assets 303,934 228,210

---




Share capital 6,350 6,313



Share premium 394,255 392,266



Legal reserves 3,757 3,718



Accumulated deficit (288,742) (297,618)




Shareholders' equity 115,620 104,679





Convertible bonds 121,277



Lease liabilities 4,340 4,363



Other financial liabilities 18,298 17,282




Non-current liabilities 143,915 21,645





Loans and borrowings 45,590



Derivative financial liabilities 147 268



Trade and other payables 42,607 36,247



Lease liabilities 1,644 1,946



Other financial liabilities 17,835




Current liabilities 44,399 101,886






Total equity and liabilities 303,934 228,210

---

Consolidated Statement of Cash Flows

For the first three months ended 31 March



Amounts in EUR'000 YTD 2020 YTD 2019




Operating result 19,446 12,244

---



Non-cash adjustments:


Depreciation, amortisation, impairment 1,704 1,353



Accrued employee benefits 666 541



Release contract liabilities (200)




Operating cash flows before changes in working
capital 21,816 13,938




Changes in working capital:



Inventories (57) 3,673



Trade and other receivables (4,827) (4,969)


Payables and other current liabilities 2,499 (2,833)


Total changes in working capital (2,385) (4,129)




Changes in non-current assets, liabilities and
equity (53) 3




Cash generated from (used in) operations before
interest and taxes 19,378 9,812




Net cash flows generated from (used in)
operating activities 19,378 9,812

---



Capital expenditure for property, plant and
equipment (597) (229)



Investment intangible assets (190) (114)



Investment in associate 7



Acquisition of license (5,500)




Net cash flows used in investing activities (6,280) (343)

---




Repayment on loans and borrowings (49,742) (7,728)



Payment of contingent consideration (18,135) (17,635)



Interests on loans (346) (2,510)



Lease liabilities (475) (379)



Convertible bond 122,682



Interest received 370 165



Proceeds of equity and warrants 495 228




Net cash flows generated from (used in)
financing activities 54,849 (27,859)

---



Increase (decrease) of cash 67,947 (18,390)



Exchange rate effects (374) 3,364


Cash and cash equivalents at 1 January 68,567 81,515




Total cash and cash equivalents at 31 March 136,140 66,489

---

Appendix: Main Financial Statements reported in US dollars

The original Financial Statements are reported in Euros. In case of differences of interpretation between the Financial Statements in US Dollars and the Financial Statements in Euros, the Financial Statements in Euros will prevail.

Principal exchange rate used for the income statement: EUR1 = $1.1050

Principal period end exchange rate used for the balance sheet EUR1 = $1.0976

Consolidated Statement of Income in US Dollars

For the first three months ended 31 March


Amounts in $ '000 except per share
data YTD 2020 YTD 2019




Revenues 54,469 40,159

---

Costs of sales (5,955) (6,179)

---

Gross profit 48,514 33,980

---

Other income 267 320

---

Research and development (8,859) (6,048)


General and administrative (5,709) (3,384)



Marketing and sales (12,725) (10,908)




Costs (27,293) (20,341)

---

Operating result 21,488 13,959

---

Fair value gain (loss) on
revaluation derivatives 134 (32)



Other financial income 409 201


Other financial expenses (8,3

78) (2,922)


Financial income and expenses (7,835) (2,753)

---

Share of net profits in associates
using the equity method 15

---

Result before income tax 13,668 11,206

---

Income tax credit (expense) (4,418) (3,397)


Net result for the period 9,250 7,809

---

Attributable to:



Owners of the parent 9,250 7,809


Total net result 9,250 7,809

---

Basic earnings per share ($) 0.015 0.013


Fully-diluted earnings per share
($) 0.013 0.011

---

Consolidated Balance Sheet in US Dollars

As at date shown



Amounts in $ '000 March 31 December 31
2020 2019

---




Intangible assets 85,196 79,405



Property, plant and equipment 9,537 9,591



Right-of-use assets 6,126 6,705



Deferred tax assets 27,784 32,061



Investment accounted for using the equity method 6,053 6,177



Restricted cash 2,532 2,543




Non-current assets 137,228 136,482





Inventories 15,927 16,223



Trade and other receivables 33,547 28,861



Cash and cash equivalents 146,896 74,348




Current assets 196,370 119,432






Total assets 333,598 255,915

---




Share capital 6,970 7,079



Share premium 432,734 439,887



Legal reserves 4,123 4,169



Accumulated deficit (316,923) (333,749)




Shareholders' equity 126,904 117,387





Convertible bonds 133,114



Lease liabilities 4,764 4,893



Other financial liabilities 20,084 19,380




Non-current liabilities 157,962 24,273





Loans and borrowings 51,125



Derivative financial liabilities 162 301



Trade and other payables 46,765 40,647



Lease liabilities 1,805 2,182



Other financial liabilities 20,000




Current liabilities 48,732 114,255






Total equity and liabilities 333,598 255,915

---

Consolidated Statement of Cash Flows in US Dollars

For the first three months ended 31 March



Amounts in $'000 YTD 2020 YTD 2019

---



Operating result 21,488 13,959

---






Non-cash adjustments:



Depreciation, amortisation, impairment 1,883 1,543



Accrued employee benefits 736 617



Release contract liabilities (228)






Operating cash flows before changes in working capital 24,107 15,891







Changes in working capital:



Inventories (63) 4,188



Trade and other receivables (5,334) (5,665)



Payables and other current liabilities 2,761 (3,230)




Total changes in working capital (2,636) (4,707)





Changes in non-current assets, liabilities and equity (59) 3






Cash generated from (used in) operations before interest and taxes 21,412 11,187






Net cash flows generated from (used in) operating activities 21,412 11,187

---




Capital expenditure for property, plant and equipment (660) (261)



Investment intangible assets (210) (130)



Investment in associate 8



Acquisition of license (6,077)






Net cash flows used in investing activities (6,939) (391)

---




Repayment on loans and borrowings (54,965) (8,811)



Payment on contingent consideration (20,039) (20,106)



Interests on loans (382) (2,862)



Lease liabilities (525) (432)



Convertible Bond 135,563



Interest Received 409 188



Proceeds of equity and warrants 547 260






Net cash flows generated from (used in) financing activities 60,608 (31,762)

---





Increase (decrease) of cash 75,081 (20,966)



Exchange rate effects (2,544) 2,282



Cash and cash equivalents at 1 January 76,891 93,245






Total cash and cash equivalents at 31 March 149,428 74,561

---

For further public information, contact:

Pharming Group N.V.
Sijmen de Vries, CEO, Tel: +31 71 524 7400
Susanne Embleton, Investor Relations Manager: +31 71 524 7400

FTI Consulting, London, UK:
Victoria Foster Mitchell, Tel: +44 203 727 1136

LifeSpring Life Sciences Communication, Amsterdam, The Netherlands:
Leon Melens, Tel: +31 6 53 81 64 27

Dit is een origineel persbericht.

ANP Pers Support, het ANP is niet verantwoordelijk voor de inhoud van bovenstaand bericht.

ANP Pers Support is een joint venture van het ANP en PR Newswire.

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234